Project Grant R21HL187010
Award Date 8/15/26
Completion Date 7/31/28
Dollars Obligated $432K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Case Western Reserve University $235,500 on April 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate plasma cell-free hemoglobin and red blood cell-derived extracellular vesicles as drivers of cardiovascular disease risk in people with HIV. The research addresses a gap in understanding why HIV-positive individuals face a twofold higher cardiovascular disease risk despite effective...
- The National Institute of Allergy and Infectious Diseases, National Institutes of Health, awarded Case Western Reserve University $467,580 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cytomegalovirus reactivation in vascular tissue of people with HIV and its contribution to cardiovascular disease. The research defines the spatial context of CMV expression in vascular tissues of people with HIV and without HIV, with and without...
- The National Heart, Lung, and Blood Institute (NHLBI) within the National Institutes of Health awarded The Ohio State University $121,658 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how inflamed adipose tissue modulates vascular inflammation through adipocyte-derived extracellular vesicles. The funded research decodes the role of adipocyte-derived extracellular vesicle cargo in promoting cardiovascular disease risk in obese populations. The...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $109,076 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop improved cardiovascular risk prediction models using advanced computational methods applied to cardiac CT imaging. The research applies deep learning to detect small, low-density calcifications on coronary artery calcium score exams that are predictive of early-stage atherosclerosis and near-term...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $4,349,952 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the phosphorylation-based molecular and functional mechanisms by which cardiac myosin binding protein C (CMYBP-C) modulates cardiac contractile function. The research employs a multidisciplinary experimental approach spanning atomic to whole-organ scales to determine how CMYBP-C conformational changes in...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University, Office of Research Administration $1,532,398 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a gene therapy delivery platform for cardiomyopathies. The project, titled "Bait and Switch Gene Therapy for Cardiomyopathies," addresses the clinical translation barrier in adeno-associated virus (AAV) gene therapy for genetic heart diseases including...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2.98 million Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) to the University of California, San Francisco to conduct a four-year research study examining the impact of asymptomatic cytomegalovirus (CMV) infection on cardiovascular event risk in people with HIV (PWH). The primary deliverable is a large-scale Mendelian randomization study that will assess whether CMV-associated plasma proteomic signatures and...
- The National Heart, Lung, and Blood Institute awarded Emory University $783,830 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 15, 2026, to conduct a prospective cohort study examining vascular endothelial function, ovarian hormones, inflammatory response, and hypertension incidence in women of reproductive age with and without HIV. The project, titled HIV and Endothelial Function in Women of Reproductive Age (HEART), will enroll 400 participants from Atlanta and...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $655,506 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanism of antibody-mediated immune enhancement during red blood cell alloimmunization. The research examines how immunoglobulin G subclasses regulate humoral immune response to red blood cell antigens, specifically how IgG2 subclasses trigger immune enhancement through Fc gamma receptor ligation on...
- The National Heart, Lung, and Blood Institute awarded $1.555 million to the University of Maryland, Baltimore on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to model and treat chronic HIV-induced lung infections. The research investigates immune mechanisms underlying increased susceptibility to respiratory infections in people living with HIV. The project focuses on how chronic HIV infection impairs dendritic cell differentiation and function, hypothesizing...